American Journal of Clinical Dermatology

, Volume 18, Issue 5, pp 613–620 | Cite as

Psoriasis, Depression, and Inflammatory Overlap: A Review

  • Nupur Patel
  • Anish Nadkarni
  • Leah A. Cardwell
  • Nora Vera
  • Casey Frey
  • Nikhil Patel
  • Steven R. Feldman
Leading Article

Abstract

Psoriasis has an enormous impact on patients’ lives and is frequently associated with depression. Depression in psoriasis may be attributed, at least in part, to elevated proinflammatory cytokines rather than the psychosocial impact of psoriasis itself. Biologics that target inflammatory cytokines treat the clinical manifestations of psoriasis, but may also play a role in reducing associated depression. Multiple biologics have decreased symptoms of depression during clinical trials in psoriasis; however, these studies used a variety of depression screening tools, which limits comparison. Furthermore, it is difficult to distinguish whether improved depression is the result of the direct anti-inflammatory effect of the biologic, or the indirect effect of improved psoriasis leading to better psychological status. Future studies evaluating depression in patients with psoriasis could benefit from a standardized depression screening tool to mitigate discrepancies and facilitate comparison across treatment types. Here, we highlight the inflammatory overlap between psoriasis and depression by examining the pathophysiology of depression, and reviewing psoriasis clinical studies that assessed depression as an outcome measure.

References

  1. 1.
    Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother. 2016;17:147–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Hrehorów E, Salomon J, Matusiak L, et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92:67–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Husted JA, Tom BD, Farewell VT, Gladman DD. Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res. 2012;64:758–65.CrossRefGoogle Scholar
  6. 6.
    Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol. 2002;138:337–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Investig Dermatol. 2015;135:984–91.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kimball AB, Wu EQ, Guérin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(651–7):e2.Google Scholar
  9. 9.
    Chosidow O, Dellavalle RP, Do D, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol. 2010;146:891–5.Google Scholar
  10. 10.
    Singhal A, Ross J, Seminog O, et al. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med. 2014;107:194–204.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Egeberg A, Hansen PR, Gislason GH, et al. Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2016;175:493–500.CrossRefPubMedGoogle Scholar
  12. 12.
    Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 1999;46:212–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull. 1993;29:389–96.PubMedGoogle Scholar
  14. 14.
    Halser G, van der Veen J, Grillon C, et al. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry. 2010;167:1226–31.CrossRefGoogle Scholar
  15. 15.
    Halser G, van der Veen J, Tumonis T, et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193–2000.CrossRefGoogle Scholar
  16. 16.
    Schatzberg AF, Lindley S. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Eur J Pharmacol. 2008;583:358–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry. 1996;1:336–42.PubMedGoogle Scholar
  18. 18.
    Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23:1109–16.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lotrich FE, El-Gabalawy H, Guenther LC, Ware CF. The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol Suppl. 2011;88:48–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Gimeno D, Kivimäki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39:413–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25:3–8.PubMedGoogle Scholar
  24. 24.
    Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Maes M, Leonard BE, Myint AM, et al. The new “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:702–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29:247–64.CrossRefGoogle Scholar
  27. 27.
    Wang J, Dunn AJ. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int. 1998;33:143–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Krügel U, Fischer J, Radicke S, et al. Antidepressant effects of TNF-α blockade in an animal model of depression. J Psychiatr Res. 2013;47:611–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43:425–73.PubMedGoogle Scholar
  30. 30.
    Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann N Y Acad Sci. 2009;1179:86–105.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Murphy BE. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol. 1991;39:239–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Setiawan E, Wilson AA, Mizrahi R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73:342–50.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Martino M, Rocchi G, Escelsior A, Fornaro M. Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr Neuropharmacol. 2012;10:97–123.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bortolato B, Carvalho AF, Soczynska JK, et al. The involvement of TNF-α in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr Neuropharmacol. 2015;13:558–76.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kissling M, Herzog C, Speck B. Effect of fleroxacin and ciprofloxacin on the formation of human mature colonies of healthy donor versus transplanted hemopoietic progenitor cells. Chemotherapy. 1991;37:212–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Scheinfeld N, Sundaram M, Teixeira H, et al. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016;22(3) (pii: 13030/qt38x5922j).Google Scholar
  39. 39.
    Wu C-Y, Chang Y-T, Juan C-K, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine. 2016;95:e3816.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Schmidt FM, Kirkby KC, Himmerich H. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression: report of two cases. Psychiatr Danub. 2014;26:288–90.PubMedGoogle Scholar
  41. 41.
    Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008;11:400–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. 2012;32:323–30.CrossRefPubMedGoogle Scholar
  44. 44.
    Guloksuz S, Wichers M, Kenis G, et al. Depressive symptoms in Crohn’s disease: relationship with immune activation and tryptophan availability. PloS One. 2013;8:e60435.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22:101–10.CrossRefPubMedGoogle Scholar
  46. 46.
    Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol. 2007;13:2089–93.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Bassukas ID, Hyphantis T, Gamvroulia C, et al. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity. J Eur Acad Dermatol Venereol. 2008;22:257–8.PubMedGoogle Scholar
  48. 48.
    Yip L, Harrison S, Foley P. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression. Australas J Dermatol. 2008;49:250–1.CrossRefPubMedGoogle Scholar
  49. 49.
    Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457–65.CrossRefPubMedGoogle Scholar
  50. 50.
    Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273–86.CrossRefPubMedGoogle Scholar
  51. 51.
    Lavda AC, Webb TL, Thompson AR. A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions. Br J Dermatol. 2012;167:970–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Moon H-S, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermatol Ther. 2013;3:117–30.CrossRefGoogle Scholar
  53. 53.
    Fortune DG, Richards HL, Kirby B, et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458–65.CrossRefPubMedGoogle Scholar
  54. 54.
    Zachariae R, Oster H, Bjerring P, Kragballe K. Effects of psychologic intervention on psoriasis: a preliminary report. J Am Acad Dermatol. 1996;34:1008–15.CrossRefPubMedGoogle Scholar
  55. 55.
    Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom. 1999;68:221–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Price ML, Mottahedin I, Mayo PR. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol. 1991;16:114–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60:625–32.CrossRefPubMedGoogle Scholar
  58. 58.
    Gaston L, Crombez J-C, Joly J, et al. Efficacy of imagery and meditation techniques in treating psoriasis. Imagin Cogn Pers. 1989;8:25–38.CrossRefGoogle Scholar
  59. 59.
    Vedhara K, Morris RM, Booth R, et al. Changes in mood predict disease activity and quality of life in patients with psoriasis following emotional disclosure. J Psychosom Res. 2007;62:611–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Investig Dermatol. 2014;134:1542–51.CrossRefPubMedGoogle Scholar
  61. 61.
    Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2015;16:22–34.CrossRefGoogle Scholar
  62. 62.
    Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–28.CrossRefPubMedGoogle Scholar
  63. 63.
    Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190–2.CrossRefPubMedGoogle Scholar
  64. 64.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–26.CrossRefPubMedGoogle Scholar
  65. 65.
    Daudén E, Griffiths CEM, Ortonne J-P, Kragballe K, Molta CT, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23:1374–82.CrossRefPubMedGoogle Scholar
  66. 66.
    Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol. 2012;26:1436–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Nupur Patel
    • 1
  • Anish Nadkarni
    • 1
  • Leah A. Cardwell
    • 1
  • Nora Vera
    • 1
  • Casey Frey
    • 1
  • Nikhil Patel
    • 1
  • Steven R. Feldman
    • 1
    • 2
    • 3
  1. 1.Department of Dermatology, Center for Dermatology ResearchWake Forest School of Medicine, Medical Center BoulevardWinston-SalemUSA
  2. 2.Department of PathologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of Public Health SciencesWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations